Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dose profile

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,467 result(s) found for: Dose profile. Displaying page 1 of 174.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002986-39 Sponsor Protocol Number: DXM/AMT Start Date*: 2011-09-12
    Sponsor Name:Profil Institut für Stoffwechselforschung GmbH
    Full Title: A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Fourfold Cross-Over Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects with Type 2 Diabetes ...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000407-24 Sponsor Protocol Number: DEX-11-01 Start Date*: 2017-02-27
    Sponsor Name:Hospira Inc
    Full Title: A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 months through <24 months
    Medical condition: intubated and mechanically ventilated pediatric subjects that require sedation in an intensive care setting for a minimum of 6 hours but not to exceed 24 hours. Subjects eligible for enrollment a...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002888-10 Sponsor Protocol Number: PCIA202/12 Start Date*: 2012-12-06
    Sponsor Name:PCI Biotech AS
    Full Title: A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-induced Photochemical Internalisation (PCI) of Gemcitabine Followed by Gemcitabine/Cisplatin Chemoth...
    Medical condition: Inoperable advanced cholangiocarcinomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054936 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) FR (Completed) LT (Prematurely Ended) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001243-27 Sponsor Protocol Number: 77108 Start Date*: 2021-12-09
    Sponsor Name:Radboudumc
    Full Title: Effect of oral magnesium supplementation on insulin sensitivity in people with type 2 diabetes
    Medical condition: People with type 2 diabetes mellitus who are treated with insulin and have a low serum magnesium concentration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002064-13 Sponsor Protocol Number: 15-HMedIdeS-06 Start Date*: 2016-10-05
    Sponsor Name:Hansa Medical AB
    Full Title: A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test
    Medical condition: Chronic Kidney Disease with donor specific antibodies (ASA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003609-24 Sponsor Protocol Number: MB09-C-01-19 Start Date*: 2021-12-30
    Sponsor Name:mAbxience Research S.L.
    Full Title: A randomised, double-blind, parallel, multicentre, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 (proposed denosumab biosimilar)...
    Medical condition: Postmenopausal women diagnosed with osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed) BG (Completed) PL (Completed) LV (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003998-26 Sponsor Protocol Number: GCT1044-01 Start Date*: 2020-05-16
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1044-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001394-16 Sponsor Protocol Number: GCT1029-01 Start Date*: 2018-03-29
    Sponsor Name:Genmab B.V.
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000985-34 Sponsor Protocol Number: 001:CD40L Start Date*: 2006-06-15
    Sponsor Name:Clinical Immunology Division
    Full Title: A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma
    Medical condition: Urinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007964-40 Sponsor Protocol Number: CL_700_018 Start Date*: 2009-02-27
    Sponsor Name:AKELA Pharma Inc.
    Full Title: A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group 12-Week Trial to Evaluate the Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration and the Current Breakthrou...
    Medical condition: Breakthrough pain in opioid tolerant cancer patients
    Disease: Version SOC Term Classification Code Term Level
    11.0 10064556 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003291-47 Sponsor Protocol Number: RHMCAN1235 Start Date*: 2017-01-25
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004979-39 Sponsor Protocol Number: MSP-2017-1220 Start Date*: 2020-08-06
    Sponsor Name:Milestone Pharmaceuticals Inc.
    Full Title: An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-etripamil nasal spray after a single dose to healthy male subjects
    Medical condition: Paroxysmal supraventricular tachycardia (PSVT)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002852-13 Sponsor Protocol Number: BPI-CT-005 Start Date*: 2006-11-21
    Sponsor Name:Bexel Pharmaceuticals Inc.
    Full Title: Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure ...
    Medical condition: dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001790-23 Sponsor Protocol Number: GCT1047-01 Start Date*: 2021-09-27
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors
    Medical condition: Malignant Solid Tumors, per protocol GCT1047-01
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004466-26 Sponsor Protocol Number: G1T28-04 Start Date*: 2017-07-10
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
    Medical condition: Locally recurrent or metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-001707-32 Sponsor Protocol Number: NIVOPTIMIZE-trial Start Date*: 2021-07-08
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
    Medical condition: Patients with advanced or metastatic melanoma or renal cell carcinoma treated with nivolumab monotherapy in a 480mg or 6 mg/kg 4 weekly scheme (either from start or after combination therapy with i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002781-23 Sponsor Protocol Number: DAP-PEDS-07-02 Start Date*: 2015-06-29
    Sponsor Name:Cubist Pharmaceuticals, Inc
    Full Title: An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who are Concurrently Receiving Standard Antibiotic Therapy for Pro...
    Medical condition: Gram-positive Infection
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003402-63 Sponsor Protocol Number: GCT1046-01 Start Date*: 2020-07-15
    Sponsor Name:Genmab A/S
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic non-small cell lung cancer (NSCLC), endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003525-42 Sponsor Protocol Number: ACH471-201 Start Date*: Information not available in EudraCT
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranopr...
    Medical condition: biopsy-confirmed C3 Glomerulopathy (C3G) or idiopathic Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and a low serum C3 level
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005382-35 Sponsor Protocol Number: CL_700_014_PRO Start Date*: 2008-08-18
    Sponsor Name:Akela Pharma Inc
    Full Title: A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate the Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration and the Current Breakthrough Pain ...
    Medical condition: Breakthrough pain in opioid tolerant cancer patients.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 12:05:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA